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Several subtypes of TBEV cause disease: European, 
Siberian, and Far Eastern (1). Siberian and Far Eastern 
have been associated with worse outcomes (1), but the po-
tentially fatal neurologic complications in this patient are 
consistent with emerging data indicating that the European 
subtype causes more severe disease than previously thought 
(4–6). In <10% of cases, TBEV targets the anterior horn of 
the spinal cord, resulting in flaccid poliomyelitis-like pa-
ralysis (3,7), or, rarer still, as in this case, in paralysis of 
respiratory muscles, requiring artificial ventilation (3,8,9).
Treatment of TBEV is supportive only; vaccination 
and avoiding mosquito bites are key to disease prevention 
and control. Although some TBEV-endemic countries have 
vaccination programs, level of uptake varies (10). Public 
health experts recommend that travelers undertaking high-
exposure activities in endemic countries get vaccinated. 
This case underscores the importance of vaccination among 
groups of susceptible people and improved awareness of 
this emerging disease. 
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We report a case of Aspergillus felis infection in a patient 
with chronic granulomatous disease who had overlapping 
features of invasive pulmonary aspergillosis and allergic 
bronchopulmonary aspergillosis. Identifying the species 
responsible for aspergillosis by molecular methods can be 
crucial for directing patient management and selection of 
appropriate antifungal agents.
A 42-year-old man with X-linked chronic granuloma-tous disease (CGD) sought care at a hospital in Paris, 
France, for a 2-week history of cough and night sweats. 
He had been receiving long-term prophylaxis with itra-
conazole (400 mg/d) and had normal trough levels (1,240 
µg/L) 1 month before his hospital visit. 
At admission, blood counts showed mild leukocyto-
sis (leukocytes 9.6 × 109 cells/L, reference range 4–10 × 
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109 cells/L), with neutrophils at 6.1 × 109 cells/L (reference 
range 1.5–7 × 109 cells/L) and eosinophils at 2 × 109 cells/L 
(reference <0.5 × 109 cells/L). Computed tomography 
(CT) revealed an upper left lobe consolidation (Appendix 
Figure, https://wwwnc.cdc.gov/EID/article/25/12/19-1020- 
App1.pdf). We administered broad-spectrum antimicrobial 
drugs (2 g meropenem 3×/d and 20 mg/kg/d amikacin). 
Results of bacterial and mycological cultures from sputum 
were negative, as was serum galactomannan. 
The patient’s condition did not improve, so we ad-
ministered liposomal amphotericin B (5 mg/kg/d) and ca-
spofungin (70 mg/d loading dose followed by 50 mg/d). 
Bronchoalveolar lavage demonstrated hypercellularity 
(1.22 × 106 cells/mL); manual differential showed 12% 
macrophages and 76% eosinophils. Results of bacterial, 
mycological, and mycobacterial cultures were negative. 
Pathology studies from a transbronchial biopsy revealed 
numerous eosinophilic granulomas alongside Charcot-
Leyden crystals (Appendix Figure). Grocott methenamine 
silver staining revealed rare septated filamentous hyphae, 
but results of mycological cultures were negative. The 
patient had elevated total serum IgE (1,210 IU/mL, refer-
ence <114 IU/mL), elevated serum A. fumigatus IgE (7 
IU/mL, reference <0.1 IU/mL) and A. fumigatus IgG (54 
IU/mL, reference <5 IU/mL), and precipitating antibodies 
to A. fumigatus (2 arcs of precipitation in immunoelec-
trophoresis). Results of parasitologic examination of fe-
cal samples and serologic testing for alternative causes of 
eosinophilia were negative.
 Eosinophilia persisted (1.8–2 × 109 cells/L) despite anti-
parasitic treatment with ivermectin (5 mg/kg/d at days 1 and 7) 
and albendazole (400 mg/d for 7 d). Pathology findings from 
a transthoracic percutaneous biopsy revealed granulomas with 
Grocott-positive septated hyphae. Result of an Aspergillus 
section Fumigati PCR on a biopsy specimen were positive, 
and mycological cultures yielded a mold morphologically 
identified as Aspergillus. After 5 weeks of liposomal ampho-
tericin B therapy (including 2 weeks of combination therapy 
with caspofungin), we switched treatment to oral voriconazole 
(loading dose of 400 mg 2×/d, followed by 200 mg 2×/d). 
Normalization of eosinophilia occurred at 6 weeks. 
We sent mycological cultures from the biopsy speci-
mens to the French National Center for Invasive Mycoses 
and Antifungals (Paris). Molecular identification based on 
the partial sequence of the internal transcribed spacer 2, 
5.8S ribosomal RNA gene, and internal transcribed spacer 2 
(525/526 bp; 99% similarity to the type strain, CBS 130245; 
GenBank accession no. KF558318.1) and the β-tubulin target 
gene enabled the identification of Aspergillus felis (109/109 
bp; 100% similarity to the type strain, CBS DTO_131-E3 
β-tubulin [benA] gene, partial cds; GenBank accession no. 
KY808576.1). The European Committee for Antimicrobial 
Susceptibility Testing (EUCAST) MICs with broth microdi-
lution methods (1) were 4 µg/L for voriconazole, 4 µg/L for 
itraconazole, 0.25 µg/L for posaconazole, 2 µg/L for caspo-
fungin, and 4 µg/L for amphotericin B. Based on EUCAST 
MIC breakpoints for A. fumigatus (2), we switched treat-
ment to oral posaconazole (loading dose of 300 mg 2×/d, 
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Table. Defining features of invasive pulmonary aspergillosis and allergic bronchopulmonary aspergillosis in a 42-year-old man with  
X-linked chronic granulomatous disease, Paris, France* 
Category 
Defining features 
IPA (oncohematologic 
setting) IPA during CGD Patient in this study ABPA 
Underlying disease Neutropenia CGD, particularly  
X-linked CGD 
X-linked CGD Asthma, cystic fibrosis 
Mechanisms of disease Angioinvasion Tissue invasion, little or 
no angioinvasion 
No angioinvasion Exaggerated 
inflammatory response 
to Aspergillus 
Course of infection Acute, single event Subacute or chronic, 
single event 
Subacute,  
single event 
Chronic with 
exacerbations 
Radiographic findings Cavitation, pulmonary 
infarction, air crescent 
sign, halo sign 
Single or multiple nodules 
and consolidations 
Single consolidation Central bronchiectasis, 
pulmonary infiltrates, 
mucus plugs 
Galactomannan testing Positive Positive or negative Negative Negative 
Total serum IgE Normal Normal Elevated  
(1,410 IU/L) Elevated (>1,000 IU/L) 
Aspergillus species-specific 
IgE or skin test reactivity 
Negative Negative Positive (7 IU/mL) Positive (>0.1 IU/mL) 
Aspergillus IgG Negative Negative Positive (54 IU/mL) Positive (>10 IU/mL) 
Precipitating antibodies to 
Aspergillus 
Negative Negative Positive (2 arcs of 
precipitation) 
Positive (>1 arc of 
precipitation) 
Blood eosinophilia Absent Absent; reported only 
during “fulminant  
mulch pneumonia” 
Present  
(2.2  109 cells/L) 
Present  
(>0.5  109 cells/L) 
First-line treatment Antifungal treatment Antifungal treatment Antifungal treatment Systemic or inhaled 
corticosteroids 
*ABPA, allergic bronchopulmonary aspergillosis; CGD, chronic granulomatous disease; IPA, invasive pulmonary aspergillosis. 
 
followed by 300 mg/d). Chest CT performed 12 months 
after treatment initiation showed noticeable improvement of 
pulmonary lesions.
Invasive pulmonary aspergillosis (IPA) remains a lead-
ing cause of death during CGD, and typically manifests as 
subacute pneumonia, with little or no angioinvasion (3). 
This patient had pulmonary infection caused by A. felis 
with overlapping features of IPA and allergic bronchopul-
monary aspergillosis (ABPA) (4). Sensitization to Asper-
gillus spp. in patients with CGD (5) and tissue eosinophilia 
in lung pathology studies during invasive fungal infections 
(6) have been reported but do not seem to be common fea-
tures of IPA in patients with CGD (3,7). There was some 
uncertainty about whether A. felis was responsible for this 
overlapping phenotype between IPA and ABPA (Table).
A. felis is a member of the A. viridinutans complex, a 
group of cryptic species belonging to Aspergillus section Fu-
migati (8). Such fumigati-mimetic molds are increasingly be-
ing recognized as sporadic causes of IPA (9). A. felis has been 
reported as a cause of sino-orbital aspergillosis in cats, but 
less frequently in humans (8). In one such case of IPA, and 
in the few reported cases in patients with CGD of IPA caused 
by the closely related A. pseudoviridinutans and A. udaga-
wae, the course of infection was more protracted than for A. 
fumigatus infections, and dissemination occurred in a con-
tiguous manner (10). Nonfumigatus Aspergillus spp. exhibit 
decreased in vitro susceptibility to commonly used antifun-
gal drugs. Most previously reported antifungal susceptibili-
ties from A. felis isolates showed high MICs for voriconazole 
and itraconazole but lower MICs for posaconazole (8). 
Because isolates may be misidentified as A. fumigatus, 
culture-based morphological identification of invasive fun-
gal infections in CGD may sometimes be insufficient. In 
cases of breakthrough fungal infections, or when faced with 
an atypical or refractory course of infection, identification 
of the fungus at a species level by molecular methods ap-
pears to be critical to guiding proper patient management.
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